Stock listing

Munich:R9Q Recce Pharmaceuticals Ltd. Aktie

German listing (Munich) of Recce Pharmaceuticals Ltd. · home listing ASX:RCE

Follow Recce Pharmaceuticals Ltd. into a list and get an email when it puts out news.

Home listing price · ASX:RCE

$0.375 AUD +0.005 (+1.4%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, ASX:RCE

Past year -9.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.375 – $0.385 AUDNov 20, 2026
Volume
35,517 sharesNov 20, 2026
Market cap
$114.7M AUDAt the close on Nov 20, 2026 · price × 305.8M shares outstanding
52-week range
$0.265 – $0.730 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$90,883 AUDMedian day 78,823 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Recce Pharmaceuticals Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
ASX:RCE · Home$0.375 AUD+0.005 (+1.4%)35,517$0.385$0.385$0.375$0.370Close on Nov 20, 2026
Frankfurt:R9Q€0.206 EUR0.000 (0.0%)—€0.206€0.206€0.206€0.206Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:RCE · AUD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.375+0.005+1.4%$0.385$0.385$0.37535,517
$0.370-0.005-1.3%$0.380$0.380$0.370104,168
$0.375+0.005+1.4%$0.375$0.380$0.36585,429
$0.3700.0000.0%$0.350$0.370$0.35016,290
$0.370+0.005+1.4%$0.370$0.370$0.35061,707
$0.365+0.005+1.4%$0.360$0.370$0.350108,196
$0.360+0.015+4.3%$0.345$0.360$0.340130,558
$0.3450.0000.0%$0.345$0.345$0.34048,852
$0.345+0.015+4.5%$0.330$0.345$0.33023,103
$0.3300.0000.0%$0.330$0.330$0.32048,608
$0.330-0.005-1.5%$0.335$0.335$0.33046,793
$0.3350.0000.0%$0.330$0.335$0.32511,865
$0.335-0.020-5.6%$0.350$0.350$0.33583,392
$0.355-0.005-1.4%$0.365$0.365$0.345118,124
$0.360+0.030+9.1%$0.345$0.365$0.34510,314,707
$0.330+0.015+4.8%$0.315$0.350$0.315255,143
$0.315+0.005+1.6%$0.300$0.315$0.290293,597
$0.310-0.015-4.6%$0.325$0.325$0.305202,951
$0.325-0.010-3.0%$0.345$0.345$0.32540,554
$0.335-0.010-2.9%$0.340$0.345$0.335126,535
$0.345-0.010-2.8%$0.350$0.350$0.33569,173
$0.355+0.005+1.4%$0.355$0.355$0.330203,787
$0.350+0.060+20.7%$0.295$0.365$0.290744,674
$0.2900.0000.0%$0.290$0.290$0.28093,370
$0.290+0.010+3.6%$0.285$0.300$0.28086,627
$0.280-0.010-3.4%$0.280$0.285$0.28015,301
$0.290+0.025+9.4%$0.270$0.290$0.26843,027
$0.265-0.025-8.6%$0.285$0.285$0.265147,062
$0.290-0.005-1.7%$0.295$0.295$0.28581,770
$0.295+0.010+3.5%$0.295$0.295$0.290159,466
$0.285-0.030-9.5%$0.298$0.298$0.285130,772
$0.3150.0000.0%$0.315$0.315$0.29514,609
$0.315+0.010+3.3%$0.310$0.315$0.290339,051
$0.305-0.020-6.2%$0.320$0.320$0.300121,963
$0.325+0.015+4.8%$0.310$0.325$0.305138,718
$0.310-0.005-1.6%$0.310$0.315$0.31018,813
$0.315-0.010-3.1%$0.325$0.325$0.30591,902
$0.325-0.005-1.5%$0.335$0.335$0.310116,595
$0.3300.0000.0%$0.335$0.340$0.32038,272
$0.3300.0000.0%$0.335$0.340$0.32574,377
$0.330-0.005-1.5%$0.335$0.335$0.325154,673
$0.335+0.010+3.1%$0.338$0.340$0.33043,877
$0.325-0.015-4.4%$0.335$0.335$0.32042,970
$0.340-0.005-1.4%$0.345$0.345$0.33013,655
$0.345+0.010+3.0%$0.340$0.345$0.33825,466
$0.335+0.005+1.5%$0.338$0.338$0.33519,844
$0.330+0.010+3.1%$0.325$0.335$0.32569,748
$0.320-0.030-8.6%$0.350$0.355$0.320277,844
$0.350-0.005-1.4%$0.350$0.350$0.34522,304
$0.355-0.015-4.1%$0.370$0.370$0.35540,381
$0.370+0.015+4.2%$0.355$0.370$0.34597,134
$0.355-0.015-4.1%$0.370$0.370$0.35029,672
$0.370+0.010+2.8%$0.360$0.370$0.345242,532
$0.360-0.010-2.7%$0.365$0.365$0.35559,963
$0.370+0.010+2.8%$0.365$0.370$0.35575,875
$0.3600.0000.0%$0.375$0.375$0.36027,753
$0.3600.0000.0%$0.370$0.370$0.35541,259
$0.360-0.015-4.0%$0.375$0.375$0.355130,690
$0.375+0.008+2.0%$0.370$0.375$0.36055,429
$0.368-0.008-2.0%$0.375$0.375$0.365116,709
$0.375-0.005-1.3%$0.380$0.380$0.370189,511
$0.380+0.005+1.3%$0.380$0.385$0.370100,215
$0.375+0.005+1.4%$0.370$0.375$0.36838,796
$0.370+0.005+1.4%$0.375$0.375$0.37021,429
$0.365-0.010-2.7%$0.375$0.375$0.365230,817
$0.375-0.010-2.6%$0.385$0.385$0.37534,406
Ticker
Munich:R9Q
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Munich
Currency
EUR

What changed lately

Latest news

Cleansing Notice

Nov 16, 2026

Closed $0.375 (+1.4%) on Nov 17, 2026

Results of Meeting

Nov 5, 2026

Closed $0.33 (0.0%) on Nov 6, 2026

AGM Presentation

Nov 5, 2026

Closed $0.33 (0.0%) on Nov 6, 2026

Options Prospectus

Nov 3, 2026

Closed $0.335 (0.0%) on Nov 4, 2026

All Recce Pharmaceuticals Ltd. news

Recce Pharmaceuticals Ltd. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
50 in the last 12 months · 269 in all · newest Nov 16, 2026 · oldest 2016
Decks
45 decks · latest Nov 6, 2026

Where Recce Pharmaceuticals Ltd. is listed

ListingExchangeCountryCurrency
ASX:RCE · Home listingASXAustraliaAUD
LS Exchange:A2ADQMLS ExchangeGermanyEUR
Stuttgart:R9QStuttgartGermanyEUR
Lang & Schwarz:A2ADQMLang & SchwarzGermanyEUR
gettex:R9QgettexGermanyEUR
Frankfurt:R9QFrankfurtGermanyEUR
OTC:RECEFOTCUnited StatesUSD
Dusseldorf:R9QDusseldorfGermanyEUR
Munich:R9Q · This pageMunichGermanyEUR
Tradegate:R9QTradegateGermanyEUR

Valuation

Statements: Year to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$122.4M AUD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Recce Pharmaceuticals Ltd. · ASX:RCEUS$75.90MUS$81.02Mn/an/an/an/an/an/an/a
Tiziana Life Sciences Ltd · NASDAQ:TLSAUS$78.98MUS$76.73Mn/an/an/an/an/an/a1.23
Nyrada, Inc. · ASX:NYRUS$78.76MUS$73.21Mn/an/an/a12.5×n/a0.0×n/a
TiumBio Co., Ltd. · KRX:321550US$76.77MUS$60.20Mn/a5.4×n/a2.9×−114.1%0.3×n/a
HLB Therapeutics Co., Ltd. · KRX:115450US$76.35MUS$66.52Mn/a1.4×n/a0.7×−28.0%0.0×n/a
Black Diamond Therapeutics, Inc. · NASDAQ:BDTXUS$75.28M−US$10.71Mn/an/an/a0.8×n/a0.2×1.76
Great Novel Therapeutics Biotech & Medicals Corp. · TPEX:7427US$73.92MUS$52.72Mn/a1,442×n/a3.2×n/a0.0×n/a
Pentixapharm Holding AG · XETR:PTPUS$73.87MUS$69.92Mn/a1,158×n/a2.4×n/a0.0×n/a
Dimerix Limited · ASX:DXBUS$73.52MUS$62.98Mn/a21.9×n/an/a−685.3%n/an/a
Faron Pharmaceuticals Oy · LSE:FARNUS$72.99MUS$57.36Mn/an/an/a5.7×n/a1.5×n/a
Cellectis S.A. · EURONEXT:ALCLSUS$72.64M−US$9.64Mn/a−0.2×n/a1.8×−115.4%2.1×n/a
Median of the othersUS$74.60MUS$61.59M13.6×2.6×−114.7%0.1×1.50

Forecasts

Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.

Price target
2.05 AUD · Analysts' mean
EPS, year to Jun 2027
-0.10 · 2 analysts
Revenue, year to Jun 2027
7.2M · 2 analysts

Team and board

Officers

OfficerRole
James GrahamManaging Director & Chief Executive Officer
Maggie NiewidokCompany Secretary
Alan DuntonChief Medical Advisor & Non-Executive Director
John PrendergastExecutive Chairman
Justin WardExecutive Director & Principal Quality Chemist
Michele DiliziaExecutive Director & Chief Scientific Officer

Board

DirectorRole
John PrendergastExecutive Chairman
Alan DuntonChief Medical Advisor & Non-Executive Director
Justin WardExecutive Director & Principal Quality Chemist
Michele DiliziaExecutive Director & Chief Scientific Officer

Events

QuarterResultsShare move
Q4 2025Aug 29, 20250.0%
Q2 2025Feb 27, 2025−1.2%
Q2 2023Feb 27, 2023 · After close+0.4%
Q4 2022Aug 31, 2022 · After close+3.8%
Q2 2022Feb 28, 2022 · Before open−1.0%
Q4 2021Aug 31, 2021+3.9%
Q2 2021Feb 25, 2021+1.0%

Open Events

Decks

DeckKindSlidesDate
Shareholder Meeting (November 2026)Shareholder meeting19 slidesNov 6, 2026
Investor Presentation (November 2026)Investor deck45 slidesNovember 2026
Investor Presentation (October 2026)Investor deck42 slidesOctober 2026
Shareholder Meeting (September 2026)Shareholder meeting10 slidesSep 2, 2026
Investor Presentation (September 2026)Investor deck42 slidesSeptember 2026
Investor Presentation (August 2026)Investor deck40 slidesAugust 2026
Q4 FY26 Earnings PresentationEarnings17 slidesJul 21, 2026
Investor Presentation (June 2026)Investor deck50 slidesJun 26, 2026
Investor Presentation (May 2026)Investor deck39 slidesMay 2026
Investor Presentation (April 2026)Investor deck39 slidesApril 2026
All 45 decks
DeckKindSlidesDate
Investor Presentation (March 2026)Investor deck39 slidesMar 19, 2026
Investor Presentation (March 2026)Investor deck41 slidesMarch 2026
Investor Presentation (November 2025)Investor deck39 slidesNovember 2025
Investor Presentation (September 2025)Investor deck38 slidesSeptember 2025
Investor Presentation (August 2025)Investor deck38 slidesAugust 2025
Investor Presentation (July 2025)Investor deck38 slidesJuly 2025
Investor Presentation (May 2025)Investor deck36 slidesMay 2025
Investor Presentation (April 2025)Investor deck36 slidesApril 2025
Investor Presentation (April 2025)Investor deck32 slidesApril 2025
Investor Presentation (March 2025)Investor deck38 slidesMar 3, 2025
Investor Presentation (March 2025)Investor deck32 slidesMarch 2025
Investor Presentation (March 2025)Investor deck35 slidesMarch 2025
Investor Presentation (January 2025)Investor deck35 slidesJanuary 2025
LifeSci Corporate Access Event 2025Conference38 slidesJanuary 2025
Investor Presentation (December 2024)Investor deck36 slidesDecember 2024
Shareholder Meeting (November 2024)Shareholder meeting18 slidesNov 6, 2024
Investor Presentation (October 2024)Investor deck36 slidesOctober 2024
Investor Presentation (March 2024)Investor deck35 slidesMarch 2024
Investor Presentation (February 2024)Investor deck35 slidesFebruary 2024
Investor Presentation (December 2023)Investor deck33 slidesDecember 2023
Investor Presentation (December 2023)Investor deck32 slidesDecember 2023
Investor Presentation (October 2023)Investor deck39 slidesOctober 2023
Investor Presentation (September 2023)Investor deck38 slidesSeptember 2023
Investor Presentation (September 2023)Investor deck39 slidesSeptember 2023
World AMR Congress 2023Conference25 slidesSeptember 2023
Investor Presentation (August 2023)Investor deck36 slidesAugust 2023
Investor Presentation (March 2023)Investor deck25 slidesMar 23, 2023
Investor Presentation (February 2023)Investor deck27 slidesFebruary 2023
Corporate Update (October 2022)Corporate update49 slidesOctober 2022
Investor Presentation (July 2022)Investor deck21 slidesJul 28, 2022
Investor Presentation (May 2022)Investor deck20 slidesMay 16, 2022
Investor Presentation (February 2020)Investor deck32 slidesFebruary 2020
Shareholder Meeting (November 2016)Shareholder meeting18 slidesNov 22, 2016
Investor Presentation (January 2016)Investor deck28 slidesJan 18, 2016
Investor Presentation (2016)Investor deck25 slides2016

Open Decks

Financings

RaiseDateIn US dollars
Secured debt facility with warrants
Terms changed: Warrants at A$0.29
Buyers: Avenue Capital Group (lender under the existing secured debt facility)
Use of proceeds: Financial flexibility to support ongoing Phase 3 clinical trial programs
Oct 16, 2026
Share purchase plan of new fully paid ordinary shares (SPP Shares) with free-attaching unlisted options
Update: up to A$4M · A$0.4 a share · Warrants at A$0.6 · Ord Minnett Limited +1
Dealers: Ord Minnett Limited (lead), SP Corporate Advisory Pty Ltd (co-lead)
Insiders: Participating directors can receive SPP Shares; their SPP Options are subject to shareholder approval at the EGM
Use of proceeds: Same purposes as the Placement
Sep 2, 2026US$2.76M
Private placement of new fully paid ordinary shares with free-attaching unlisted options
Announced: A$4M · A$0.4 a share · Warrants at A$0.6 · Ord Minnett Limited +1
Dealers: Ord Minnett Limited (lead), SP Corporate Advisory Pty Ltd (co-lead)
Use of proceeds: Strengthen balance sheet for Middle Eastern licensing deal, clinical trials, IND-enabling activities and working capital
Jun 26, 2026US$2.76M
Private placement of new fully paid ordinary shares
Announced: A$5M · A$0.28 a share
Use of proceeds: Commencement and completion of one of the Phase III clinical trials
Apr 10, 2025US$3.1M
Rights offering of new fully paid ordinary shares
Announced: up to A$10.8M · A$0.28 a share
Insiders: Each of the Directors who are Eligible Shareholders intends to participate in the Entitlement Offer
Use of proceeds: Other programs currently in development by the Company
Apr 10, 2025US$6.7M

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in AUD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue7.51M5.03M4.37M3.08M1.64M1.12M679.6K1.29M139.3K
Cost of revenue356.4K10.4M7.22M217.2K187.7K295.6K200.8K56.1K53.1K25.5K
Gross profit-356.4K-2.94M-2.19M4.15M2.90M1.34M920.9K623.5K1.24M113.8K
Research and development10.2M7.04M7.17M6.22M5.56M1.99M416.4K372.2K999.4K
Selling, general and administrative8.68M8.46M5.87M4.11M2.37M6.81M1.75M1.60M1.34M1.54M
Operating income-23.2M-22.9M-22.1M-17.3M-14.2M-15.4M-5.41M-3.42M-2.92M-3.18M
Depreciation and amortization356.4K356.2K366.8K217.2K187.7K295.6K200.8K56.1K53.1K25.5K
EBITDA-22.8M-22.5M-21.7M-17.1M-14.0M-15.1M-5.21M-3.36M-2.87M-3.16M
Interest expense1.66M1.26M846.9K183.3K11.9K12.1K56.4K56.7K54.3K2.41K
Income before tax-23.8M-21.4M-22.6M-17.4M-14.1M-15.1M-5.39M-3.47M-2.96M-3.16M
Income tax-8.88M-6.74M-4.91M-4.31M-3.08M-1.57M-1.07M-679.6K-1.29M-139.3K
Net income-15.0M-21.4M-17.7M-13.1M-11.0M-13.5M-4.32M-2.79M-1.67M-3.03M
Earnings per share, basic-0.05-0.09-0.10-0.07-0.06-0.09-0.03-0.03-0.02-0.04

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents2.69M10.4M4.42M1.56M11.6M20.9M2.68M403.4K679.7K1.09M
Short-term investments236.6K207.9K47.0K20.1K0
Receivables3.87M435.3K159.4K90.7K582.7K245.5K41.4K36.5K21.0K60.2K
Inventory135.4K-36.5K-21.0K-60.2K
Current assets7.12M11.4M5.14M1.95M12.2M21.2M2.74M453.1K708.5K1.15M
Property, plant and equipment1.03M1.23M608.4K438.7K500.6K504.7K469.1K435.2K310.6K
Total assets8.53M12.4M6.37M2.56M12.6M21.7M3.24M922.2K1.14M1.46M
Accounts payable8.20M2.18M3.97M948.9K481.4K487.3K159.5K124.4K125.4K255.4K
Current liabilities16.3M6.13M15.1M4.85M2.45M1.08M885.2K1.27M416.4K690.3K
Long-term debt8.30M8.60M0161.3K
Total debt10.4M10.8M811.2K250.6K74.8K126.9K83.2K737.4K2.86K322.6K
Total liabilities25.3M15.5M15.9M5.14M2.56M1.18M931.5K1.33M448.8K874.4K
Shareholders' equity-16.7M-3.05M-9.52M-2.59M10.1M20.5M2.31M-405.6K694.9K590.1K
Shares outstanding289.2M237.0M177.1M175.7M175.9M157.0M128.5M95.4M85.6M77.4M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-9.89M-20.4M-13.0M-12.7M-9.01M-7.86M-3.81M-2.61M-1.73M-2.50M
Capital spending-62.0K-26.3K-141.9K-38.6K-40.3K-76.0K-5.94K-89.9K-177.8K-246.1K
Free cash flow-9.95M-20.5M-13.2M-12.7M-9.05M-7.93M-3.81M-2.70M-1.91M-2.74M
Cash from investing123.6K-443.9K-141.9K-38.6K-40.3K-76.0K-5.94K-89.9K-177.8K-246.1K
Cash from financing2.01M26.9M16.0M2.71M-240.5K26.1M6.09M2.43M1.50M243.0K
Dividends paid-1.72M-1.72M-1.72M0
Share buybacks102.0K-1.72M-1.72M-1.72M1.69M1.45M0
Change in cash-7.75M6.03M2.85M-10.0M-9.29M18.2M2.28M-276.3K-410.7K-2.50M

Open Financials

Filings

FilingDateTypeFiled with
Cleansing NoticeNov 16, 2026FinancingASX
Application for quotation of securities - RCENov 16, 2026FinancingASX
Notification regarding unquoted securities - RCENov 13, 2026Other filingsASX
Final Director's Interest Notice - Mr McKeoughNov 6, 2026Ownership change noticeASX
Results of MeetingNov 5, 2026Meeting outcomeASX
AGM PresentationNov 5, 2026Other filingsASX
Retirement of Mr Alistair McKeough as Non-Executive DirectorNov 4, 2026Management or board changeASX
Options ProspectusNov 3, 2026Offer documentASX
Cleansing NoticeOct 30, 2026FinancingASX
Application for quotation of securities - RCEOct 30, 2026FinancingASX
Show 200 filings
FilingDateTypeFiled with
Quarterly Activities/Appendix 4C Cash Flow ReportOct 29, 2026Quarterly reportASX
Quarterly Activities/Appendix 4C Cash Flow ReportOct 29, 2026Quarterly reportASX
License and Commercialisation Agreement in AUS/NZ for R327GOct 21, 2026Operations updateASX
License and Commercialisation Agreement in AUS/NZ for R327GOct 21, 2026Acquisition or disposalASX
Independent Review of Indonesian Phase 3 R327G Trial DataOct 19, 2026Operations updateASX
Independent Review of Indonesian Phase 3 R327G Trial DataOct 19, 2026Operations updateASX
Notification regarding unquoted securities - RCEOct 16, 2026Other filingsASX
Amendments to Debt Facility with Avenue Capital GroupOct 16, 2026FinancingASX
Amendments to Debt Facility with Avenue Capital GroupOct 16, 2026FinancingASX
Notice of Annual General Meeting/Proxy FormOct 6, 2026Meeting noticeASX
Notification of cessation of securities - RCEOct 1, 2026FinancingASX
Resolutions under section 249N of the Corporations ActSep 29, 2026Other filingsASX
2026 Annual General MeetingSep 18, 2026Meeting noticeASX
Results of General MeetingSep 1, 2026Meeting outcomeASX
General Meeting PresentationSep 1, 2026Other filingsASX
Appendix 4E and FY26 Annual ReportAug 31, 2026Annual reportASX
Appendix 4GAug 31, 2026Other filingsASX
HREC Approves Comparator Study for Pivotal Phase 3 DFIAug 18, 2026Operations updateASX
Change of Director's Interest Notices (x4)Aug 6, 2026Ownership change noticeASX
Cleansing NoticeAug 4, 2026FinancingASX
Application for quotation of securities - RCEAug 2, 2026FinancingASX
Completion of Share Purchase Plan and Shortfall NoticeJul 30, 2026FinancingASX
Application for quotation of securities - RCEJul 30, 2026FinancingASX
Notice of General Meeting/Proxy FormJul 30, 2026Proxy formASX
U.S. Government Releases US$66.9B AMR Biodefense StrategyJul 29, 2026Operations updateASX
Vietnamese Patent Granted for RECCE Anti-InfectivesJul 13, 2026Other filingsASX
AUD $3.7M Income Tax Refund ReceivedJun 30, 2026ResultsASX
Placement & SPP to raise $8 millionJun 25, 2026FinancingASX
HREC Approval Accelerates Global Phase 3 DFI StrategyJun 21, 2026Operations updateASX
Addendum to Recce Signs Middle East Licensing Term SheetMay 27, 2026Other filingsASX
Recce Signs Middle East Licensing Term SheetMay 26, 2026Other filingsASX
Brazil Patent Granted for RECCE Anti-InfectivesMar 24, 2026Other filingsASX
RCE Investor Webinar Presentation DeckMar 19, 2026Other filingsASX
Appendix 4D and Interim Financial ReportFeb 27, 2026Interim reportASX
Recce Enters Second U.S. Department of Defense R&D AgreementFeb 1, 2026Operations updateASX
Quarterly Activities/Appendix 4C Cash Flow ReportJan 30, 2026Quarterly reportASX
AUD $5.3m R&D Rebate ReceivedJan 13, 2026ResultsASX
RCE Awarded Advanced Overseas Finding up to A$85mDec 15, 2025FinancingASX
Hong Kong Patent Granted for RECCE Anti-InfectivesNov 26, 2025Other filingsASX
Positive Efficacy Data for Inhaled R327 in HAP/VAP ModelNov 25, 2025Other filingsASX
Patient Dosing Underway in Ph 3 Indonesia DFI TrialSep 25, 2025Operations updateASX
Preliminary Final ReportAug 29, 2025ResultsASX
R327G Highly Effective in Burn Wounds ModelAug 12, 2025Other filingsASX
Recce Signs Debt Facility with Avenue Capital GroupJun 17, 2025FinancingASX
Successful Placement of Entitlement Offer ShortfallJun 3, 2025FinancingASX
China Patent Accepted for RECCE Anti-InfectivesMay 26, 2025Other filingsASX
Recce Enters into USA Department of Defense R&D AgreementApr 27, 2025Other filingsASX
Entitlement Offer - Offer Booklet and Access LetterApr 22, 2025Offer documentASX
Phase II Clinical Trial Receives Additional Approval for DFIApr 22, 2025Operations updateASX
Placement and Entitlement Offer to Fund Phase III TrialsApr 10, 2025FinancingASX
Key Opinion Leader PresentationMar 2, 2025Operations updateASX
Japan Patent Allowance for RECCE Anti-InfectivesFeb 25, 2025Other filingsASX
Positive Phase II Data from Clinical Trial of R327 GelFeb 16, 2025Other filingsASX
Trading HaltFeb 13, 2025Trading halt or suspensionASX
Pause in TradingFeb 13, 2025Trading halt or suspensionASX
Correction to Appendix 4C and Quarterly Activities ReportFeb 6, 2025Quarterly reportASX
Patient Dosing Complete in Phase II ABSSSI Trial of R327GJan 20, 2025Other filingsASX
Regulatory Approval for Registrational Phase 3 R327G TrialDec 8, 2024Operations updateASX
Australia Patent Granted for RECCE Anti-InfectivesNov 25, 2024Other filingsASX
AUD $6.75m R&D Rebate ApprovedNov 13, 2024ResultsASX
Ethics Approval for Registrational Ph3 R327G Clinical TrialNov 10, 2024Other filingsASX
AGM PresentationNov 5, 2024Meeting noticeASX
Phase II ABSSSI Clinical Trial Advances to Final StagesNov 4, 2024Operations updateASX
Efficacy Data & Approval to Continue Ph II ABSSSI TrialOct 27, 2024Other filingsASX
Ph II ABSSSI Trial Recruitment and Dosing Passes HalfwayOct 8, 2024Other filingsASX
Notice of Special General Meeting/Proxy FormOct 8, 2024Proxy formASX
Successful Completion of Share Purchase PlanAug 4, 2024FinancingASX
US Department of Defense Grants US $2m for R327GJul 15, 2024Other filingsASX
R327 Efficacy against WHO Priority Pathogen Acinetobacter BJul 8, 2024Other filingsASX
Placement & SPP to raise $10 million - Funded to FY26Jul 2, 2024FinancingASX
Phase I/II UTI/Urosepsis Rapid Infusion Trial CompleteJun 27, 2024Other filingsASX
Ethics Approval Broadens to All Topical InfectionsJun 24, 2024Operations updateASX
Further R&D Rebate ApprovedJun 18, 2024FinancingASX
R327 added to WHO List of Antibacterial ProductsJun 18, 2024Other filingsASX
Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical TrialJun 10, 2024Operations updateASX
Ph I/II UTI/Urosepsis Trial Dosing Commenced in Next CohortMay 15, 2024Operations updateASX
MCRI Pilot Study- Positive Efficacy Data for Lung InfectionsMay 9, 2024Operations updateASX
China Patent Granted for RECCE Anti-InfectivesMay 6, 2024Other filingsASX
Safety Committee Approves High Dose of 4,000mgApr 26, 2024Operations updateASX
Recce Completes 5,000 R327 Doses Per Week under GMPApr 16, 2024Operations updateASX
Recce Pharmaceuticals - Business UpdateApr 7, 2024Operations updateASX
Patent Granted in Israel for RECCE Anti-InfectivesApr 2, 2024Other filingsASX
Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical TrialMar 12, 2024Operations updateASX
Recce Receives AUD $11.17m R&D AdvanceMar 7, 2024Other filingsASX
Safety Committee Approves Expansion of Ph I/II DFI TrialFeb 25, 2024Operations updateASX
RCE Establishes Strategic Partnership in South-East AsiaFeb 5, 2024Operations updateASX
Positive Ph I/II DFI Efficacy Data to Support Site ExpansionJan 17, 2024Other filingsASX
Murdoch Children's R327 Efficacy UTI in-vivoDec 27, 2023Other filingsASX
RCE Awarded Further $11.17m Advanced Overseas FindingDec 15, 2023FinancingASX
RCE Awarded $43.7m AusIndustry Advanced Overseas FindingDec 14, 2023FinancingASX
Murdoch Children's R327 Efficacy N.gonorrhoeae in-vivoDec 13, 2023Other filingsASX
Canadian Patent Granted for RECCE Anti-InfectivesNov 22, 2023Other filingsASX
Subjects Dosed Over 15 mins in UTI/Urosepsis Clinical TrialNov 6, 2023Other filingsASX
Committee Approves Fast 15-Min Infusion in Ph I/II UrosepsisOct 23, 2023Other filingsASX
Completes Cohort Dosing UTI/Urosepsis Rapid Infusion TrialSep 22, 2023Operations updateASX
Placement and Entitlement OfferSep 11, 2023FinancingASX
Opening R&D Address at World AMR CongressSep 7, 2023Operations updateASX
RECCE Trademark Registered - VietnamSep 6, 2023Other filingsASX
Additional Positive Patient Cases - Special Access SchemeAug 31, 2023Other filingsASX
Appendix 4E and Unaudited Preliminary ReportAug 31, 2023ResultsASX
Next Dose Cleared in Rapid Infusion Phase I/II UTI TrialAug 28, 2023Other filingsASX
Patients Dosed in R327 Diabetic Foot Infection TrialAug 22, 2023Other filingsASX
Phase I/II Burn Wound Infection Trial Stage 1 CompleteAug 21, 2023Other filingsASX
Positive Patients Update - Special Access SchemeAug 7, 2023Other filingsASX
Australian Patent Granted for RECCE Anti-InfectivesAug 3, 2023Other filingsASX
Bonus Canadian R&D Rebate ReceivedJul 28, 2023Other filingsASX
Scientia Completes Cohort Dosing in Phase I/II UTI TrialJul 28, 2023Other filingsASX
Scientia Doses Ahead of Schedule in Phase I/II UTI TrialJul 24, 2023Other filingsASX
Clarification - 5x Higher Concentration in Urine & PlasmaJul 20, 2023Other filingsASX
Phase I Clinical Trial Data Review CompleteJul 19, 2023Other filingsASX
A$801,604 R&D Rebate Advance ReceivedJul 12, 2023Other filingsASX
First Cohort Dosed in Rapid Infusion Phase I/II UTI studyJul 10, 2023Other filingsASX
Ethics Approval for Phase I/II UTI Trial ExpansionJun 29, 2023Other filingsASX
Ethics Approval to Start Phase I/II (I.V.) Clinical TrialApr 17, 2023Other filingsASX
New Family 4 Patent to be Granted for RECCE Anti-InfectivesApr 10, 2023Other filingsASX
Recce Receives Further A$973,144 R&D AdvanceApr 4, 2023Other filingsASX
Corporate Presentation - WI Emergence 2023Mar 22, 2023Other filingsASX
Recce Selects CMAX for Phase I/II UTI Clinical TrialFeb 19, 2023Other filingsASX
A$6.21m Received from R&D Rebate PaymentsJan 24, 2023Other filingsASX
JP Morgan Healthcare ConferenceJan 10, 2023Other filingsASX
Australian Patent to be Granted for RECCE Anti-InfectivesJan 9, 2023Other filingsASX
Anti-Infective Research Unit est. at Murdoch ChildrensDec 15, 2022Other filingsASX
Approval to Start Phase I/II Diabetic Foot Ulcer StudyDec 8, 2022Other filingsASX
Anti-Infective Portfolio Update and Webinar detailsOct 18, 2022Other filingsASX
Pause in tradingOct 17, 2022Trading halt or suspensionASX
R327 COVID Study UpdateOct 17, 2022Other filingsASX
Expansion and Acceleration of Clinical ProgramsSep 27, 2022Other filingsASX
Appendix 4EAug 31, 2022ResultsASX
Phase I Clinical Trial of R327 I.V. - 6000mg CompleteAug 21, 2022Other filingsASX
Corporate Presentation - Aussie Equities Day 2022Jul 28, 2022Other filingsASX
Phase I Positive Safety Data - 4000mg CompleteJun 21, 2022Other filingsASX
Phase I Clinical Trial R327 Advances to 4000mgMay 20, 2022Other filingsASX
Corporate Presentation - Biotech Investor LunchMay 16, 2022Other filingsASX
Phase I Clinical Trial R327 Advances to High Dose CohortApr 12, 2022Other filingsASX
Anti-Viral Patent Granted in Hong KongApr 11, 2022Other filingsASX
Positive safety data from 4th Cohort -Phase I Clinical TrialMar 29, 2022Other filingsASX
$3.08m R&D Rebate ReceivedMar 28, 2022Other filingsASX
Safety Committee Clears PhI R327 Dose IncreaseMar 6, 2022Other filingsASX
S&P DJI Announces March 2022 Quarterly RebalanceMar 4, 2022Other filingsASX
Positive Safety Continues in 3rd Cohort PhI Clinical TrialFeb 20, 2022Other filingsASX
Positive Safety Data from Third Cohort of PI Clinical TrialFeb 7, 2022Other filingsASX
Positive Safety Data from Second Cohort of PI Clinical TrialJan 18, 2022Other filingsASX
Positive Safety Data from Phase 1 Clinical TrialJan 6, 2022Other filingsASX
Patients to be Dosed in Ph 1 IV Clinical Trial of R327Dec 14, 2021Other filingsASX
Update on Phase I/II Clinical Trial for Burn Wound InfectionDec 6, 2021Other filingsASX
Appendix 4C and Activity ReportOct 29, 2021Quarterly reportASX
Ethics Approval to Start Phase 1 Intravenous Clinical TrialOct 24, 2021Other filingsASX
Reinstatement to Official QuotationOct 12, 2021Trading halt or suspensionASX
Court Orders GrantedOct 11, 2021Legal or regulatory actionASX
Suspension from Official QuotationOct 11, 2021Trading halt or suspensionASX
Trading haltOct 8, 2021Trading halt or suspensionASX
R327 Phase I Clinical Trial Registered on ANZCTRSep 30, 2021Other filingsASX
Recce Receives Further Innovation Connections GrantAug 11, 2021Other filingsASX
Anti-Viral Patent Granted in USA for RECCE Anti-InfectivesJul 22, 2021Other filingsASX
Anti-Viral Patent Granted in ChinaJul 20, 2021Other filingsASX
Outstanding Efficacy Against Flesh-Eating BacteriaJul 19, 2021Other filingsASX
Multiple Patients Dosed in Topical Phase I/II Clinical TrialJul 11, 2021Other filingsASX
Recce Clinical Pipeline UpdateJun 7, 2021Other filingsASX
R327 Demonstrates World First Multiple Mechanisms of ActionMay 27, 2021Other filingsASX
R327 to Stage 2 of SARS-CoV-2 Antiviral Screening at CSIROMay 19, 2021Other filingsASX
Positive Data on RECCE 327 Against All Six ESKAPE PathogensMay 3, 2021Other filingsASX
RECCE 327 Registered for Topical Burns Study in HumansApr 15, 2021Other filingsASX
Positive Sinusitis Patient Update - Special Access SchemeApr 7, 2021Other filingsASX
Positive Sinusitis Data Against InfectionMar 31, 2021Other filingsASX
Anti-Viral Patent Granted in EU for RECCE Anti-InfectivesMar 30, 2021Other filingsASX
S&P DJI Announces March 2021 Quarterly RebalanceMar 12, 2021Other filingsASX
Recce Pharmaceuticals Dual Lists on Frankfurt Stock ExchangeMar 7, 2021Other filingsASX
Appendix 4D and Half Yearly ReportFeb 25, 2021Interim reportASX
Recce Applies for Dual Listing on Frankfurt Stock ExchangeFeb 23, 2021Other filingsASX
Fiona Stanley Hospital Phase I/II Clinical Trial AgreementFeb 15, 2021Other filingsASX
Further Encouraging COVID Results at DohertyFeb 11, 2021Other filingsASX
R&D Incentive Rebate ReceivedFeb 3, 2021Other filingsASX
Positive Intranasal Animal Data against SARS-CoV-2 in StudyDec 22, 2020Other filingsASX
RCE Awarded AusIndustry Advanced Overseas Anti-Viral FindingDec 7, 2020Other filingsASX
Recce Awarded AusIndustry Advanced Overseas (R&D) FindingNov 25, 2020Other filingsASX
Anti-Viral Patent Granted in Japan for RECCE Anti-InfectivesNov 22, 2020Other filingsASX
Encouraging Results Against SARS-CoV-2 VirusNov 10, 2020Other filingsASX
HREC Approval to Start Phase I/II Burns Wound StudyOct 15, 2020Other filingsASX
Murdoch Childrens Research Institute, R435 Against H.PyloriSep 30, 2020Other filingsASX
Recce Completes Capital Raising of $27.95mSep 23, 2020FinancingASX
R327 Phase I Study - Australias CMAX Clinical FacilitySep 10, 2020Other filingsASX
Positive & Concentration-Dependent Efficacy Against COVID-19Sep 8, 2020Other filingsASX
Recce Pharmaceuticals Receives Innovation Connections GrantAug 31, 2020Other filingsASX
Recce Pharmaceuticals Appoints James Graham as CEOAug 28, 2020Other filingsASX
Positive Oral Data on New RECCE 435 Against H. pyloriAug 4, 2020Other filingsASX
US Researchers to Test RECCE in Expanded SARS-CoV-2 ProgramJul 16, 2020Other filingsASX
RCE Selected by CSIRO/PDI for SARS-CoV-2 Antiviral ProgramJul 8, 2020Other filingsASX
Response to ASX Price and Volume QueryMay 27, 2020Explanation requestASX
Positive Data on RECCE 327 Against Neisseria gonorrhoeaeMay 4, 2020Other filingsASX
Further Positive Data on RECCE 327 Against MRSA SuperbugApr 23, 2020Other filingsASX

This page holds 200 of 263 filings. Open Filings

Open Filings

Cap table

Built by 6ix from Recce Pharmaceuticals Ltd.’s releases · as of Jun 26, 2026

Common shares
305,770,071
Fully diluted
305,770,071

Fully diluted

LineShares
Common shares305,770,071

Share count over time

CountShares
Nov 22, 2026305,770,071

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Alan DuntonChief Medical Advisor & Non-Executive Director · Since at least Apr 23, 2025
Alistair McKeoughNon-Executive Director · Nov 4, 2026 – Nov 4, 2026 · Past
James GrahamManaging Director & Chief Executive Officer · Since at least Apr 23, 2025
John PrendergastExecutive Chairman · Since at least Apr 10, 2025
Justin WardExecutive Director & Principal Quality Chemist · Since at least Nov 5, 2026
Maggie NiewidokCompany Secretary · Since at least Nov 4, 2026
Michele DiliziaExecutive Director & Chief Scientific Officer · Since at least Nov 5, 2026
SYDNEY AustraliaNon-executive Director · Until Nov 4, 2026 · Past

Open People

Log in to ask 6ix AI your own questions about Recce Pharmaceuticals Ltd.